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ABSTRACT
Objectives: To summarise the evidence for generic
prognostic factors across a range of musculoskeletal
(MSK) conditions.
Setting: primary care.
Methods and outcomes: Comprehensive systematic
literature review. MEDLINE, CINAHL, PsychINFO and
EMBASE were searched for prospective cohort studies,
based in primary care (search period—inception to
December 2015). Studies were included if they
reported on adults consulting with MSK conditions and
provided data on associations between baseline
characteristics (prognostic factors) and outcome.
A prognostic factor was identified as generic when
significantly associated with any outcome for 2 or
more different MSK conditions. Evidence synthesis
focused on consistency of findings and study quality.
Results: 14 682 citations were identified and 78
studies were included (involving more than 48 000
participants with 18 different outcome domains). 51
studies were on spinal pain/back pain/low back pain,
12 on neck/shoulder/arm pain, 3 on knee pain, 3 on
hip pain and 9 on multisite pain/widespread pain. Total
quality scores ranged from 5 to 14 (mean 11) and 65
studies (83%) scored 9 or more. Out of a total of 78
different prognostic factors for which data were
provided, the following factors are considered to be
generic prognostic factors for MSK conditions:
widespread pain, high functional disability,
somatisation, high pain intensity and presence of
previous pain episodes. In addition, consistent
evidence was found for use of pain medications not to
be associated with outcome, suggesting that this factor
is not a generic prognostic factor for MSK conditions.
Conclusions: This large review provides new evidence
for generic prognostic factors for MSK conditions in
primary care. Such factors include pain intensity,
widespread pain, high functional disability, somatisation
and movement restriction. This information can be used
to screen and select patients for targeted treatment in
clinical research as well as to inform the management of
MSK conditions in primary care.
INTRODUCTION
Musculoskeletal (MSK) conditions, such as
back pain and knee pain, are common
presentations in primary care making up to
one-third of all primary care consultations.1 2
They are the leading cause of disability
worldwide3 and represent a burden on the
individual, healthcare systems and society
that is expected to increase in the coming
years as people live longer.4 This has led to a
growing interest in the prognosis of these
conditions, to understand symptom progres-
sion and identify distinct patterns of
symptom trajectories. In the absence of clear
underlying aetiological mechanisms or
strong evidence for large treatment effects5
information about the prognosis of MSK con-
ditions becomes even more important in
their management.6
Prognostic factors have been deﬁned as
characteristics that are associated with clin-
ical outcomes in patients with a given health
condition.7 Identifying prognostic factors
and developing prognostic models can help
predict the individual patient’s outcome.8 An
example is the presence of multisite MSK
pain which has been found to be associated
with poor future outcomes of psychological
Strengths and limitations of this study
▪ A large comprehensive review—14 682 citations
identified, 78 studies included (more than
48 000 participants with 18 different outcome
domains).
▪ The first review to summarise evidence for indi-
vidual generic prognostic factors for musculo-
skeletal (MSK) conditions.
▪ A focus on primary care—but it is in this setting
where MSK conditions are most commonly
managed, and it is the primary care clinicians
who would benefit most from using the concept
of generic prognostic factors in discussing and
planning the management with patients.
▪ Inability to perform a meaningful meta-analysis
—heterogeneity of outcome measures, with dif-
ferent measuring tools, differing measuring
property and different follow-up points.
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health, functional limitations and work disability.9–11
Prognostic factors that are found to be associated with
treatment effect (effect modiﬁers or moderators) can
potentially help predict response to speciﬁc treatments,
and allow better targeting of treatments to those who
are most likely to beneﬁt or experience least harm from
it (stratiﬁed medicine). For example, prognostic tools
can be used to stratify patients with low back pain into
‘risk groups’ for whom particular treatments are shown
to be most beneﬁcial.12 13
Although prognostic factors have been described for a
wide range of MSK conditions, they have often been
studied for individual regional symptoms, such as back,
neck or elbow pain.14–16 While there are differences in the
presentation and likely underlying pathology, evidence sug-
gests that MSK conditions often share a similar clinical
course on average, and similar prognostic factors may
predict outcome.17 Furthermore, nearly half of people with
MSK conditions report pain in more than one site.11 18 19
For these reasons, it would be particularly useful to look
for prognostic factors across a range of MSK conditions,
regardless of their anatomical site or assumed pathological
origin.20 In 2007, a systematic review21 explored this, and
was able to evidence the presence of such ‘generic’ factors
across a number of regional MSK conditions identiﬁed in
individual studies. Since 2007, many more individual
studies have been published reporting prognostic factors
for various regional MSK conditions. Combining ﬁndings
from these studies might help strengthen the evidence for
generic factors, as identiﬁed in the original review, and
identify other factors not yet identiﬁed.
Our aim was to systematically summarise the evidence
from studies that investigated prognostic factors for MSK
conditions in primary care, building and expanding on
the previous review by Mallen et al.21 The objectives are
to extract data on prognostic factors from included
studies and synthesise the evidence for generic prognos-
tic factors deﬁned as a factor that was found to be sig-
niﬁcantly associated with outcome for two or more
different regional MSK conditions, regardless of the
number of studies in which this was assessed.
METHODS
Literature search and study selection
We used the same search strategy as the systematic review
of generic prognostic factors for MSK conditions by
Mallen et al21 (see online supplementary appendix 1).
We searched the computerised bibliographic databases
of MEDLINE, CINAHL, PsychINFO and EMBASE for
studies published from the end date of the search of the
previous review (April 2006)21 to December 2015. The
search combined terms for prognostic studies (eg, prog-
nosis, course), MSK conditions (eg, neck, shoulder,
hand, back, joint) and primary care (eg, general prac-
tice, family physician).
Eligible studies had to be prospective cohort studies,
based in primary care or equivalent (direct access)
healthcare settings and included adults consulting with
regional MSK pain ( joint, site-speciﬁc or multiple-site).
They had to provide data on a measure of association
between baseline characteristics (prognostic factors) and
outcome. Excluded were studies among patients with
inﬂammatory pain conditions (eg, gout, polymyalgia
rheumatica) and studies only involving the analysis of
medical records, and secondary analyses of data from
randomised controlled trials. Studies published in
English were considered for inclusion. When multiple
articles for a single study were identiﬁed, information
was extracted from all published articles.
Identiﬁed citations and abstracts were shared equally
(50% each) by two authors (PC and MA) and screened
independently for eligibility. Full texts of potentially eli-
gible articles were then retrieved and again shared by
the same two authors and reviewed for eligibility inde-
pendently. The two authors (PC and MA) then retrieved
a random selection of 10 articles which they both
screened in order to check consistency on inclusion
eligibility.
Data extraction and quality assessment
Included articles were shared by two authors (PC and
MA) and data extraction and quality assessment con-
ducted independently. Consistency of data extraction
and quality assessment was checked on a random sample
of 10 papers prior to the main data extraction. The ﬁnd-
ings reported in this review are from all studies included
in the earlier and the current reviews combined.
The following information was extracted from each
included article: ﬁrst author, publication date, setting
and country, sample size and participants’ age and
gender, anatomical pain site, primary outcome mea-
sures, and frequency and duration of follow-up. Other
information included pain site and potential prognostic
factors (participant’s demographics and pain character-
istics). Details of the association between potential prog-
nostic factors and outcome were also collected,
including the strength of association (eg, OR, relative
risk (RR), difference in mean outcome scores), signiﬁ-
cance level and adjustment for covariates.
The same tool for assessing the quality of included
studies used in Mallen et al21 was used here. This is a
checklist consisting of 15 items that cover aspects related
to internal and external validity. Items were scored posi-
tive (+) if present and satisfactory, negative (–) if absent
or unsatisfactory, and unclear (?) if the article did not
contain enough information to make an accurate assess-
ment. The ﬁnal quality score for individual studies was
based on the sum of the positive scores. Although there
are arguments against the use of summary quality scores
for individual studies,22 we decided, with caution, to use
summary scores to facilitate our evidence synthesis,
which takes study quality into account when summaris-
ing results regarding generic prognostic factors across
studies. To estimate the inﬂuence of using a predeﬁned
cut-point for identifying high-quality studies, we
2 Artus M, et al. BMJ Open 2017;7:e012901. doi:10.1136/bmjopen-2016-012901
Open Access
conducted a sensitivity analysis to explore the use of
other cut-points (see below).
Evidence synthesis
The review focussed on identifying generic prognostic
factors for MSK conditions in primary care. A potentially
generic prognostic factor was deﬁned as a factor that
was found to be signiﬁcantly associated with outcome
for two or more different regional MSK conditions, for
example, hip and shoulder pain, regardless of the
number of studies in which this was assessed. Wide het-
erogeneity of study populations, treatments received and
outcome measures precluded meta-analysis, and there-
fore evidence was synthesised taking into account statis-
tical signiﬁcance of associations, consistency of results
and study quality.
Signiﬁcant association with outcome was deﬁned as a
univariable association, or an association adjusted for
confounding or other prognostic variables, with a p value
<0.05, or an OR or RR with 95% CIs not including
1. Results were considered to be consistent if ≥75% of
the studies reporting on the factor showed the same dir-
ection of the association with outcome. For study quality,
an a priori decision was made to use a cut-off of more
than 9 out of a total of 15 (60%) to deﬁne a study as
‘high quality’ versus a score of 9 or less for ‘low quality’.
Four levels of evidence were adapted from Sackett
et al23 and Ariens et al24 which take into account consist-
ency of signiﬁcant results as well as methodological
quality (table 1).
Only factors assessed at baseline or at initial consult-
ation were considered for analysis. When studies
included multiple outcomes or different outcome
domains (such as return to work, pain persistence), or
different follow-up points (eg, 6 months and 1 year), any
statistically signiﬁcant association with any outcome at
any follow-up time was taken as evidence for the factor’s
potential prognostic value.
With regard to deﬁning MSK pain regions, a prag-
matic approach was adopted to group studies according
to the pain regions they described, to reduce duplication
and to replicate the approach adopted in the review by
Mallen et al.21 Studies on neck, shoulder and arm pain
were grouped together. Studies on ‘spinal pain’, ‘back
pain’ and ‘low back pain’ were grouped together
because studies on ‘spinal pain’ and ‘back pain’ often
included patients who had lower as well as upper back
pain without distinction. Studies that described their
patients as having ‘MSK pain’ or ‘joint pain’ without spe-
cifying a region were grouped together with studies that
explicitly included patients with ‘multisite pain’ or ‘wide-
spread pain’. If a single study included groups of
patients each with a different regional pain complaint,
potentially generic prognostic factors were identiﬁed
separately for each of those pain groups if such informa-
tion was provided separately in the article.
Sensitivity analyses
To assess the robustness of our evidence synthesis, a
number of sensitivity analyses were carried out. To examine
the inﬂuence of using a cut-point for study quality, analysis
was carried out on different quality cut-offs: a lower cut-off
of 50% (total score of 7.5) and higher cut-off of 75% (total
score of 11). Results were also examined regardless of study
quality score. To assess whether the synthesised overall evi-
dence was inﬂuenced by study sample size, a sensitivity ana-
lysis was conducted by repeating the analyses, but
excluding studies with small sample size. As there is no con-
sensus on what deﬁnes a small observational study, two arbi-
trary cut-off sample size values of 100 and 200 participants
were used for this purpose.
RESULTS
Study selection
In total, 14 682 independent citations were identiﬁed in
the systematic electronic search (ﬁgure 1). In total,
13 763 were excluded on screening of titles and further
639 on screening abstracts. Eighty-one full articles
reporting on 78 studies met all selection criteria and
were included in the review. This included the 45 arti-
cles included in the earlier review.21
Study characteristics
The 78 included studies were conducted in Australia,
North America and Europe, and investigated prognostic
factors for MSK pain among more than 48 000 patients
in primary care (individual study size ranging from 44
to 4325 patients). In total, 51 studies were on spinal
pain/back pain/low back pain, 12 on neck/shoulder/
arm pain, 3 on knee pain, 3 on hip pain and 9 on
multisite pain/widespread pain. Characteristics of the
included studies are presented in online supplementary
appendix 2 and citations in online supplementary
appendix 3.
Table 1 Levels of evidence for generic prognostic factors
for poor outcome for musculoskeletal pain
Level of
evidence Definition
Strong Consistent significant findings (≥75%) in
studies of high quality, at least 2 studies
Moderate Consistent significant findings (≥75%) in
studies of high and low quality with at
least one study of high quality in the
direction of consistent significant
findings
Weak Significant findings of only one study of
high quality or consistent significant
findings (≥75%) in studies of low quality
Inconclusive Significant findings in less than 3
studies of low quality, or inconsistent
significant findings (regardless of
quality)
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Overall, 18 different outcome domains were used; the
most frequently used were physical functioning (in 37
studies) and pain severity (in 23 studies). However,
various outcome measures were used within these
domains. For physical functioning, measures included
the Roland-Morris Disability Questionnaire (RMDQ),
the Oswestry Disability Inventory (ODI), and the
Medical Outcome Short Form-36 Health Survey (SF-36).
For pain severity, measures included Visual Analogue
Scale (VAS), Numeric Rating Scale (NRS), days with
pain and 1–7 point ordinal scale. In addition, composite
scales were used for pain and physical functioning, such
as the Chronic Pain Grade (CPG) questionnaire, the
Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) and the Shoulder Pain
and Disability Index (SPADI). Outcomes within the
domain of return to work were used in 17 studies
(return to work in good health, days of sick leave,
absence from work, ability to work), patient perceived
recovery in 10 (global perceived recovery, global per-
ceived effect), persistence of symptoms in 11 and use of
healthcare services and medications in 7 studies.
Recurrence of the symptom was used in two studies.
Each of the following outcomes were used in one study
each: neck pain questionnaire, survival, time to general
practitioner visit, presence of knee pain, receiving acu-
puncture, catastrophising, pain-related fear, recovery
expectation, quality of life and hip replacement. Length
of follow-up ranged from 2 weeks to 10 years (median
12 months, mean 18 months). Owing to the diversity of
outcome measures used in the studies, the tools to
measure them, the properties of those tools and the
time points they were measured at, it was not possible to
conduct separate analyses for associations with speciﬁc
outcome measures.
Quality of included studies
Information was provided by the included studies to
allow for assessment of the majority of quality items
(table 2). Items for which there was sufﬁcient informa-
tion and were considered satisfactory most frequently are
‘standardised collection of data’ and ‘appropriate design
Figure 1 Results of literature
search and study selection. MSK,
musculoskeletal; RCT,
randomised controlled trial.
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for the study question’ (each in 77 studies, 99%). The
quality item that was considered unsatisfactory most fre-
quently was ‘sample size calculation’, which was missing
or inappropriate in all but one study.25 Information was
unclear for some quality items, most frequently baseline
participation of more than 70% of study sample (unclear
in 28 studies (36%) and representativeness of the study
sample (unclear in 12 studies (15%)).
Total quality scores for individual studies ranged from
5 to 14 (mean 11, median 11). Out of a possible
maximum score of 15 (all quality items satisﬁed), 65
studies (83%) scored more than 9 points and were con-
sidered as high-quality studies (see online
supplementary appendix 4).
Prognostic factors
Information on a total of 78 different prognostic factors
was provided in at least one of the included studies
(table 3).
Sixty-three factors were investigated for only one pain
region, and so evidence was not available for these
factors to be considered as generic prognostic factors.
For the other 15 factors, data were available for their
association with outcomes for two or more pain regions,
and were therefore considered as potential generic prog-
nostic factors. The number of pain regions in which
these 15 factors were studied ranged from 2 (for heavy
lifting: back and shoulder) to 9 (for gender), in a
number of studies ranging from 1 (for heavy lifting)26 to
45 (for pain duration). Table 4 lists the studies that pro-
vided evidence for each of the 15 potentially generic
prognostic factors, grouped according to the regional
MSK conditions they studied. Only two factors (social
support and heavy lifting) were studied with regard to
only two MSK conditions. All the remaining potential
generic prognostic factors were from studies on four or
more MSK pain sites.
The overall level of evidence for each potential
generic prognostic factor, taking into account the
number of studies and their methodological quality, is
presented in table 5.
Using both the number of studies providing evidence
and their methodological quality, segregating studies
according to the cut-off for high quality, strong evidence
for being a generic prognostic factor indicating a poor
prognosis was found for: widespread pain, high func-
tional disability and somatisation. Evidence was moder-
ate for high pain intensity, long pain duration and high
depression/anxiety score and weak for history of previ-
ous pain episode, poor coping strategy and movement
restriction. Strong evidence was also found from mul-
tiple high-quality studies for the absence of association
between outcome and low level of education. Evidence
for lack of association was moderate for use of pain med-
ications and weak for older age and gender and there-
fore these factors are not generic prognostic factors.
Evidence from the available studies was not conclusive
for poor social support and heavy lifting.
The number of studies that provided evidence for
each of the generic factors varied widely. For the factors
for which evidence was conclusive, the number of
studies providing the evidence ranged from 10 studies
for movement restriction to 46 for pain duration (mean
20 studies, median 18). For the two factors for which evi-
dence was considered inconclusive, four studies pro-
vided evidence for poor social support and only one
study for heavy lifting.
Sensitivity analyses
Using a lower total study quality score cut-off of 50%
(total score of 7.5) and higher cut-off of 75% (total
score of 11) did not change the overall evidence for the
generic prognostic factors. Moreover not including
quality scores in summarising the overall evidence and
Table 2 Number of studies in which information on individual methodological quality assessment items was satisfactory,
unsatisfactory or unclear
Quality item Yes No Unclear
Standardised collection of data 77 0 1
Appropriate design for study question 77 0 1
Clearly defined study objective 76 1 1
Appropriate selection of outcome 75 2 1
Appropriate analysis of outcomes measured 73 2 3
Appropriate measure of outcome 71 4 3
Numerical description of important outcomes given 68 9 1
Adequate length of follow-up for research question 67 9 2
Inclusion/exclusion criteria clear and appropriate 61 12 4
Representative sample (and comparison) 61 5 12
Losses and drop outs <20% 49 24 5
Adjusted and unadjusted calculations provided (with CI if appropriate) 44 31 3
Adequate description of losses and drop outs 42 33 3
Baseline participation >70% (all groups) 32 18 28
Sample size calculation provided 1 77 0
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only relying on the number of studies, in another sensi-
tivity analysis, also did not change the overall evidence
for the generic prognostic factors.
Regarding study sample size, using the lower cut-off
sample size of 100 participants, only ﬁve of the included
studies included <100 participants. These ﬁve studies,
which were all scored as high quality, showed signiﬁcant
associations between outcomes and several prognostic
factors (functional disability, pain intensity, pain dur-
ation, depression and anxiety, movement restriction,
age). Excluding these studies did not inﬂuence the
weight of evidence for the association between prognos-
tic factors and outcomes.
Using the higher sample size cut-off of 200 partici-
pants, 24 studies would be identiﬁed as small (<200 par-
ticipants). In total, 22/24 of these studies were of high
quality and contributed evidence for signiﬁcant associ-
ation between outcomes and most potential generic
prognostic factors. When excluding these 24 small
studies from the evidence synthesis, evidence remained
strong only for presence of widespread pain, high func-
tional disability and somatisation as generic prognostic
factors (see online supplementary appendix 5). In add-
ition, overall evidence became consistent and therefore
strong for high pain intensity and previous history of
similar episode of pain.
DISCUSSION
This comprehensive systematic review provides evidence
for generic prognostic factors for across a range of MSK
conditions in primary care. Based on 78 studies, the
majority of which were of high methodological quality,
the following factors are considered to be generic prog-
nostic factors for MSK conditions: widespread pain, high
functional disability, somatisation, high pain intensity and
presence of previous pain episodes. In addition, consist-
ent evidence was found for use of pain medications not
to be associated with outcome, suggesting that this factor
is not a generic prognostic factor for MSK conditions.
These ﬁndings are important. They are the product of
a comprehensive search of the literature providing evi-
dence from a large number of high-quality studies since
an earlier review was published just under 10 years
ago.21 The focus of this review was on primary care as it
is in this setting where MSK conditions are most com-
monly managed, and it is the primary care clinicians
who would beneﬁt most from using the concept of
generic prognostic factors in discussing and planning
the management with patients. The large number of
studies in this review, reﬂecting the growing interest in
assessing prognosis of MSK pain, adds clarity and
strength to identifying generic prognostic factors for
MSK conditions. A recent systematic review limited to
patients with subacute non-malignant pain, that also
included studies on headache, provided evidence on the
presence of generic prognostic factors.27 That review
only assessed the association of prognostic factors with
functional disability and absence from work. It found
that multisite pain, high pain severity, older age, baseline
disability and longer pain duration were identiﬁed as
potential prognostic factors for disability, which has over-
laps with the current ﬁndings. A cohort study among
Table 3 Prognostic factors that were investigated in the
included studies
1. Abdominal pain 40. Leg pain
2. Activity avoidance 41. Living with a partner
3. Age 42. Monotonous repetitive
work
4. Aggressiveness 43. Neurological signs
5. Back surgery 44. Pain better at rest
6. BMI 45. Pain control
7. Bone density 46. Pain in thoracic area
8. Bothersomeness 47. Pain intensity
9. Catastrophising 48. Pain medication
10. Comorbidity 49. Pain on examination
11. Compensation 50. Patient beliefs
12. Consultation for knee
pain
51. Pay scale
13. Coping 52. Perceived cause as
accident or trauma
14. Decision authority 53. Perceived disability
15. Depression/anxiety 54. Perceived risk of
persistence
16. Disability 55. Perceived self-efficacy
17. Drinking coffee 56. Persistence of pain
18. Duration 57. Previous treatment
19. Education 58. Quadriceps strength
20. Employment 59. Recurrence
21. Ethnicity 60. Resilience
22. Expectation of
recovery
61. Responses of important
others
23. Fear avoidance 62. Satisfaction with
management
24. Financial impact of
LBP
63. Self-reported health (poor)
25. Frailty 64. Sleep quality
26. Gender 65. Smoking
27. GP advice wait and
see
66. Social support
28. GP advise physical
exercise
67. Socioeconomic status
29. GP estimation of risk 68. Somatisation
30. GP improve posture
advice
69. Specific diagnosis
31. Hand grip strength 70. Sport, physical activity
32. Headache 71. The physician listened
carefully
33. Heavy lifting 72. Physical trauma
34. Hypochondriasis 73. Waist circumference
35. In unionised job 74. Weak personal control
36. Job satisfaction 75. Widespread pain
37. Job seniority 76. Work ability
38. Kinesiophobia 77. Work absence
39. Knee pain at
follow-up
78. Work security
BMI, body mass index; GP, general practitioner; LBP, low back
pain.
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patients with non-spinal MSK pain20 is one of few studies
that used direct ‘comparisons’ between prognostic
factors and pain intensity outcome. It found that having
had the same symptom in the previous year, a lower
level of education, lower scores on the SF-36 vitality sub-
scale, using pain medication at baseline and being both-
ered by the symptom more often in the past 3 months
were associated with poor improvement in pain intensity
over time regardless of the location of pain. The differ-
ence between these ﬁndings and ours might be
explained by the fact that prognostic factors in these two
studies were investigated only in association with speciﬁc
outcomes. For the factor of age, we found evidence for
association with outcomes in 15 studies, and for no asso-
ciation in 26. It is arguable that the ﬁndings related to
this factor might be different if speciﬁc outcomes were
selected, and similarly if different pain sites were
selected. Our deﬁnition of generic prognostic factors
was across all MSK conditions regardless of site or
outcome measures.
The potential application and utility of prognostic
factors for research and clinical practice is well
Table 4 Studies that provided evidence significant association between potentially generic prognostic factors and poor
outcomes.
Prognostic factors
Significant
association n
Neck/shoulder/
arm (n 11) Spinal/back (n 41)
Hip
(n 3)
Knee
(n 3)
General
musculoskeletal
(n 7)
Widespread pain,
present
Yes 20 14, 35, 36, 44,
48, 50, 69
15, 18, 21, 24, 33, 49, 52, 10 − 63 25, 57, 72, 78
No 6 − 51, 53, 61, 68 − 64 58
Disability, high Yes 18 12, 35, 36 2, 3, 9, 13, 15, 20, 24, 31, 33,
39
10, 22
28 42 26
No 2 − 45, 74 − − −
Somatisation,
present
Yes 12 35, 44, 48 15, 34, 38, 61, 70, 77, 10 − 42 22
No 2 69 67 − − −
Pain intensity, high Yes 27 14, 35, 36, 44,
48
8, 13, 15, 16, 24, 33, 34, 37, 39,
41, 45, 49, 53, 56, 65, 73, 10,
68
28 42 7, 26
No 12 50, 69 9, 18, 31, 61, 67, 74, 60 64 58, 78
Pain duration, long Yes 31 12, 14, 35, 36,
44, 50, 69
2, 3, 8, 13, 15, 16, 18, 19, 21,
31, 33, 39, 45, 49, 56, 61, 66,
77, 1, 10, 60
28,
40
42 −
No 15 47, 48, 71 9, 20, 24, 38, 53, 65, 67, 70, 22,
68
− 63 57
Depression/anxiety,
high
Yes 17 − 6, 13, 15, 19, 34, 38, 49, 56, 73,
74, 10, 32
− − 7, 23, 25, 58, 78
No 10 48 24, 60, 65, 66, 67, 70, 77, 68 − 64 −
Previous episodes,
present
Yes 16 12, 35, 36, 44,
75
3, 9, 19, 21, 34, 41, 49, 53, 61 − 42 57
No 11 47, 50, 71 20, 31, 38, 45, 51, 67, 68 − − 7
Coping strategies,
poor
Yes 12 35, 36, 71 15, 49, 52, 53, 10, 32, 43 − − 7, 78
No 6 69 61, 77, 60, 68 − − 58
Movement
restriction, present
Yes 6 12 21, 29, 70 28 − 58
No 4 − 9, 20, 60 − − 78
Level of education,
low
Yes 4 − 49, 61 − 63 57
No 11 69, 71 51, 56, 65, 66, 67, 68 − 64 58, 78
Use of pain
medication
Yes 2 71 − − − 57
No 6 50 51, 56, 66, 67 46 − −
Age, older Yes 16 36, 35 8, 21, 33, 38, 41, 45, 56, 66, 67 − 42, 63 25, 58, 78
No 26 44, 48, 69, 71,
62
9, 18, 20, 24, 31, 49, 51, 53, 61,
65, 70, 77, 1, 22, 60, 62, 68
40,
46
64 7, 57
Gender, female Yes 5 50, 75 49, 66, 77 − − −
No 15 69, 71 51, 53, 61, 65, 67, 70, 68, 60 46 63, 64 57, 58
Social support,
poor
Yes 2 35 − − 42 −
No 2 − 74 − − 78
Heavy lifting,
present
Yes 1 62 62 − − −
No 0 − − − − −
*Citations of included studies are presented in online supplementary appendix 3.
Studies grouped according to pain site. High-quality studies are shown in bold.*
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recognised.7 They could help inform patients, clinicians
and researchers about the likely course of the condi-
tion, and enable clinicians to identify patients at high
or low risk of poor outcome to aid decisions on further
investigations or more extensive treatment. Prognostic
factors could also be used to enable clinicians to target
speciﬁc types of treatment to particular patients with a
particular prognostic proﬁle. The STarT Back Tool is
an example of such a tool that was found to be effect-
ive in managing patients with low back pain.13
Identifying subgroups of patients according to their
prognostic proﬁle would also enable better understand-
ing and interpretation of response to treatment in clin-
ical trials. Modiﬁable factors, such as movement
restrictions or depression/anxiety, could represent
potential targets for treatments investigated in clinical
research. Other factors, such as presence of widespread
pain or pain duration, could also be used to investigate
differential treatment effects in subgroups of
participants.
Generic prognostic factors, compared with individual
prognostic factors for individual MSK conditions, have
additional and arguably superior utility in that they help
support a generic approach in research and clinical
management. Targeting these factors as potential treat-
ment effect modiﬁers or moderators is one example of
such potential. Clinically, for patients presenting with
shoulder, knee or back pain or a combination of these
pains, for instance, trying to memorise and explore indi-
vidual prognostic factors for each of these pain condi-
tions assuming they are different and distinct, will at best
be difﬁcult and at worst confusing. Exploring generic
factors that apply to any and all MSK conditions, regard-
less of pain region, helps focus the discussion between
the clinician and the patient and the concluding
message.
Apart from gender, age, level of education and use of
pain medications, the remaining 55 factors that were
studied but not considered as generic could not be com-
pletely ruled out as potential generic MSK prognostic
Table 5 Level of evidence for significant association of the potentially generic prognostic factors with poor outcomes and
mean (range) of total quality scores for high-quality versus low-quality studies
Association with poor outcome
Significant association
present
Significant association
absent
Prognostic factors Quality n Quality score Quality n Quality score Overall evidence
Widespread pain, present High 18 12 (11–14) High 4 11.5 (10–13) Yes, associated, strong
Low 2 9 Low 2 6.5 (5–8)
Disability, high High 16 12 (10–14) High 2 12 Yes, associated, strong
Low 2 9 Low 0 −
Somatisation, present High 10 12 (10–14) High 2 12.5 (11–14) Yes, associated, strong
Low 2 9 Low 0
Pain intensity, high High 25 12 (12–14) High 10 11.5 (10–14) Yes, associated, moderate
Low 2 8.5 (8–9) Low 2 6.5 (5–8)
Pain duration, long High 27 12 (10–14) High 12 12 (11–14) Yes, associated, moderate
Low 4 8 (8–9) Low 3 8.5 (8–9)
Depression/anxiety, high High 15 13 (10–14) High 8 12.5 (11–14) Yes, associated. moderate
Low 2 8.5 (8–9) Low 2 7 (5–8)
Previous episodes, present High 16 12 (10–13) High 10 12 (10–14) Yes, associated, weak
Low 0 − Low 1 8
Coping strategy, poor High 9 12 (10–14) High 4 11 (10–13) Yes, associated, weak
Low 3 8 (8–9) Low 2 8
Movement restriction, present High 6 11.5 (10–13) High 3 11 Yes, associated, weak
Low 0 − Low 1 8
Level of education, low High 3 12 (10–13) High 9 12.5 (10–13) Not associated, strong
Low 1 9 Low 2 6.5 (5–8)
Use of pain medication High 2 12.5 (12–13) High 5 12.5 (11–14) Not associated, moderate
Low 0 Low 1 9
Age, older High 15 12 (11–14) High 18 11.5 (10–13) Not associated, weak
Low 1 9 Low 8 7.5 (5–9)
Gender, female High 5 13 High 10 12 (10–14) Not associated, weak
Low 0 − Low 5 8 (5–9)
Social support, poor High 2 13 High 2 13 Inconclusive
Low 0 − Low 0 −
Heavy lifting, present High 0 − High 0 − Inconclusive
Low 1 5 Low 0 −
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factors. Evidence was not available to make this judge-
ment, and high-quality studies need to examine their
association with outcomes to provide such evidence.
The number of studies that investigated different MSK
conditions varied considerably. Back pain was studied in
the vast majority of studies, just under 70%, compared
with 16% for neck/shoulder/arm pain and only 4%
each for knee and hip and 10% on multisite/widespread
pain. Although this reﬂects and represents the preva-
lence of these presentations in primary care,1 it also
indicates a need to assess prognostic factors in these
latter conditions to be able to safely conclude whether
there are other potentially generic prognostic factors.
Our sensitivity analyses showed that evidence for some
generic prognostic factors was derived from small cohort
studies and therefore less robust (in particular age,
depression, coping strategies, movement restriction).
Obtaining evidence from further larger, high-quality
studies on these factors would also help strengthen the
evidence for the generic prognostic factors we identi-
ﬁed. Another area to explore in future research is to
identify prognostic factors that might be found consist-
ently associated with particular MSK pain condition but
not with others. Such factors might be considered as
speciﬁc for those MSK conditions.
Limitations
Including ﬁndings from clinical trials was considered,
but as trial participants compared with those of observa-
tional studies are often highly selected, have different
characteristics with different data collection methods
and different types of treatment, often have different
expectations regarding treatment, which we know may
inﬂuence prognosis, and may therefore be more (or
less) likely to take part in research. Also, treatment is
closely controlled in trials and even usual care arms are
not identical to actual care in most cases (they are often
best care rather than usual care), and this may make a
difference to the prognostic factors identiﬁed. Another
potential point might be that trials only measure factors
relevant to the trial, whereas cohort studies are more
likely to explore a wide range of factors relevant to prog-
nosis. So we might get a biased selection of prognostic
factors if data were obtained from randomised con-
trolled trials. All these would have potentially inﬂuenced
our ﬁndings regarding prognosis and prognostic factors.
A limitation associated with the use of a list of quality
items and total quality score, is the inability to discrimin-
ate between studies based on particular individual items,
as some quality items would potentially have greater
weighting in the assessment of bias. To investigate this
potential limitation, a sensitivity analysis was performed
using a different total score cut-off, which may have miti-
gated the issue of impact of individual items, although
might not completely resolve it.
One challenge we faced in this review was the inability
to perform a meaningful meta-analysis because of the
heterogeneity of outcome measures, with different
measuring tools, differing measuring property and dif-
ferent follow-up points. This deprived us of the ability to
provide a quantitative estimate of the predictive per-
formance of the generic prognostic factors for particular
outcomes. It is arguable that some factors are generic
for particular outcomes and not others. It would be
plausible to expect some factors to be more strongly
associated with outcomes than others. Equally, the
strength of predictive performance of the factors might
depend on the number of pain sites it is associated with.
The results of this review help shed important light on a
number of generic prognostic factors that need to be
further studied in future research. A clearer understand-
ing of the roles of these generic factors is an important
next step and could be generated through meta-analysis
of individual patient data from studies.
CONCLUSION
We have identiﬁed strong evidence to support the pres-
ence of a number of generic prognostic factors that are
associated with poor outcomes for MSK conditions,
regardless of pain site. Such factors include pain inten-
sity, widespread pain, high functional disability, somatisa-
tion and movement restriction. This information can be
incorporated into the management of MSK conditions
in primary care.
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